Provided by Tiger Trade Technology Pte. Ltd.

Centessa Pharmaceuticals plc

26.77
-0.2000-0.74%
Post-market: 26.770.00000.00%19:09 EST
Volume:948.60K
Turnover:25.20M
Market Cap:3.91B
PE:-14.70
High:27.12
Open:26.92
Low:26.00
Close:26.97
52wk High:30.58
52wk Low:9.60
Shares:146.00M
Float Shares:97.13M
Volume Ratio:0.92
T/O Rate:0.98%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.8212
EPS(LYR):-2.0595
ROE:-60.62%
ROA:-25.26%
PB:12.96
PE(LYR):-13.00

Loading ...

Centessa’s ORX489 Phase 1 Trial: Early Safety Readout to Watch for CNTA Investors

TIPRANKS
·
Yesterday

Centessa Pharmaceuticals Initiated at Outperform by Wolfe Research

Dow Jones
·
Feb 24

Centessa initiated with an Outperform at Wolfe Research

TIPRANKS
·
Feb 24

Centessa Pharmaceuticals Announces Advisory Compensation Terms for Former CEO Saurabh Saha

Reuters
·
Feb 14

Nxera Pharma Receives $1.8 Million Milestone Payment from Centessa Pharmaceuticals

Reuters
·
Feb 12

Centessa Pharmaceuticals Chief Legal Officer Iqbal J. Hussain Reports Disposal of Common Shares

Reuters
·
Feb 04

Centessa Pharmaceuticals nimmt an mehreren internationalen Investorenkonferenzen teil

Reuters
·
Feb 03

Centessa Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 29

Truist Financial Remains a Buy on Centessa Pharmaceuticals (CNTA)

TIPRANKS
·
Jan 29

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Lexicon Pharmaceuticals (LXRX) and Alkermes (ALKS)

TIPRANKS
·
Jan 16

Centessa Pharmaceuticals (CNTA) Gets a Buy from Leerink Partners

TIPRANKS
·
Jan 14

Nxera Pharma Receives US$3.6 Million Milestone Payment from Centessa

Reuters
·
Jan 13

Can ORX750’s Sleep-Disorder Promise Redefine Centessa Pharmaceuticals’ (CNTA) Competitive Positioning in Neurology?

Simply Wall St.
·
Jan 10

Centessa Pharmaceuticals Is Maintained at Buy by Truist Securities

Dow Jones
·
Jan 09

Centessa price target raised to $33 from $30 at Truist

TIPRANKS
·
Jan 08

Centessa Pharmaceuticals Issues Amended UK Employment Agreement

Reuters
·
Jan 07

Centessa Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
Jan 02

Centessa Pharmaceuticals PLC - Appoints Mario Alberto Accardi As CEO

Reuters
·
Dec 11, 2025

Centessa Pharmaceuticals Names Mario Alberto Accardi CEO

MT Newswires Live
·
Dec 11, 2025

Press Release: Centessa Pharmaceuticals Announces CEO Transition as Company Advances Strategy to Extend Orexin Leadership into Multiple Neuroscience Indications

Dow Jones
·
Dec 11, 2025